A study on immune-related adverse events developing in malignant tumor patients treated with immune checkpoint inhibitors in our hospital

immune-related adverse events study in Saitama Medical University International Medical Center - SMU-IMC-irAE study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000060126

Enrollment

1000

Registered

2026-04-01

Start date

2023-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

immune-related adverse events

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with malignant tumors who received treatment with immune checkpoint inhibitors

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Age, gender, type of malignant tumor and duration of disease, type of ICI used for treatment, presence or absence of irAE, type of irAE, time to onset of irAE, confirmation of immune abnormalities such as autoantibodies, details of irAE treatment, continuation of ICI after irAE occurrence	—

Countries

Japan

Contacts

Public ContactYasuto Araki

Saitama Medical University International Medical Center Department of Hospital Medicine

arakiya@saitama-med.ac.jp042-984-4111

Outcome results